← Back to Search

Kinase Inhibitor

BOS172738 for Non-Hematologic Cancers

Phase 1
Waitlist Available
Research Sponsored by Boston Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up a minimum of approximately 3 months
Awards & highlights

Study Summary

This trial will study the safety and if it is tolerated when given to patients with advanced solid tumors that have a RET gene alteration. They will also study what the maximum tolerated dose is.

Eligible Conditions
  • Advanced Non-Hematologic Cancers

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~a minimum of approximately 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and a minimum of approximately 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximum tolerated dose (MTD) of BOS172738
Number of participants with any TEAE leading to study drug discontinuation
Number of participants with any non-serious TEAE
+4 more
Secondary outcome measures
Duration of Complete Response (DoCR)
Duration of Response (DoR)
Objective Disease Control Rate (ODCR)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: BOS172738Experimental Treatment1 Intervention
In Part A (dose escalation), participants with advanced solid tumors with rearranged during transfection (RET) gene alterations will receive oral BOS172738 at a starting dose of 10 milligrams (mg) once daily in each 28-day cycle. In Part B (dose expansion), participants with RET gene-fusion non-small cell lung cancer (NSCLC), with RET gene-mutant medullary thyroid cancer (MTC), and with RET gene-altered advanced tumors or NSCLC/MTC with prior specific RET gene-targeted therapy will be enrolled in Cohorts 1, 2, and 3, respectively, and will receive oral BOS172738 once daily in each 28-day cycle at the recommended Phase 2 dose (RP2D) established in Part A.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BOS172738
2018
Completed Phase 1
~120

Find a Location

Who is running the clinical trial?

Boston PharmaceuticalsLead Sponsor
11 Previous Clinical Trials
645 Total Patients Enrolled

Media Library

BOS172738 (Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03780517 — Phase 1
Non-Hematologic Cancers Research Study Groups: BOS172738
Non-Hematologic Cancers Clinical Trial 2023: BOS172738 Highlights & Side Effects. Trial Name: NCT03780517 — Phase 1
BOS172738 (Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03780517 — Phase 1
~18 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top